P

Precision AQ

Data-driven drug access and launches

Regulatory and Start Up Specialist

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's, Master's, PharmD, PhD, MD
Remote in Spain
RemoteRemote role based in Spain.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A bachelor's degree in life sciences or a related field, ideally in a scientific or healthcare discipline, or Registered Nurse (RN) status, or an equivalent combination of education, training, and experience.
  • Demonstrated experience in contracts and budgeting negotiation.
  • Previous experience as a Regulatory or Start Up Specialist in a contract research organization or pharmaceutical/biotechnology industry, or equivalent relevant experience and/or demonstrated competencies.
  • Strong communication and organizational skills.
  • Experience using computerized information systems, electronic spreadsheets, word processing, and electronic mail.
  • Fluency in English and Spanish.
  • Candidates must be legally authorized to work in the country of employment without employer sponsorship.
Responsibilities
  • Deliver site activation readiness on time and to quality standards for assigned countries and sites, and foresee and mitigate risks.
  • Prepare Clinical Trial Application forms and initial and amended/notification submission dossiers for Competent Authorities, Ethics Committees, and other applicable local bodies, in accordance with local requirements and timelines, to obtain authorizations and approvals for clinical trials under applicable regulations, company standard operating procedures, and International Council for Harmonisation Good Clinical Practice principles.
  • Interact with Competent Authorities and Ethics Committees for study purposes and handle their responses.
  • Provide regular updates on Competent Authority and Ethics Committee submissions to the assigned Start Up Lead and/or Regulatory Lead and to the Project Manager or Project Team.
  • Maintain project plans, project trackers, and regulatory intelligence tools relevant to assigned responsibilities, keeping Regulatory Leadership informed.
  • Prepare or support development of study-specific start-up plans, investigational medicinal product release requirements, and essential document review criteria.
  • Partner with the assigned site Clinical Research Associate to align communications and secure the site.
  • Review and manage collection of essential documents required for site activation and investigational medicinal product release.
  • Customize country- and site-specific Patient Information Sheets and Informed Consent Forms.
  • Facilitate translation and coordinate document translations.
  • Maintain communication with Feasibility, Clinical Operations, Project Management, Regulatory, and Site Contracts Management on project-specific status and deliverables for country start-up.
  • Act as subject matter expert for collection and maintenance of site-level critical-path-to-site-activation data points, including Competent Authority and local Institutional Review Board/Ethics Committee timelines, site contracts, budget negotiation requirements, and other reviews needed for timely activation of assigned sites.
  • When required, participate in or support negotiation of study budgets and execution of investigator contracts under the direction of the Site Contract Management department or designee.
  • May support the Feasibility group in site outreach to assess investigator interest in a potential study.
  • Maintain current knowledge of local clinical-trial laws and regulations and help distribute that knowledge within Precision for Medicine to support compliant clinical-trial conduct.
  • Maintain audit and inspection readiness and file documents in the relevant Trial Master File according to the TMF plan and/or study-specific plans.
  • May support the clinical team in conducting Pre-Study Site Visits.
Desired Qualifications
  • A qualification in Pharmacy or work experience as a Pharmacist.
  • Fluency in Portuguese.
  • Relevant regulatory and site start-up experience, including feasibility, contract negotiations, and Competent Authority, Ethics Committee, or Institutional Review Board submissions.
  • Experience using milestone tracking tools or systems.
  • Ability to prioritize workload to meet deadlines.
  • An advanced degree in medical or life sciences (MD, PhD, or PharmD), Regulatory Affairs Professionals Society certification, or a Master's in Regulatory Science.

About the company

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Get referred to Precision AQ

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • February 17, 2026 hires Yahya Anvar and Emma Hawe deepen AI and HTA capabilities.
  • August 12, 2026 Candice Subero hire boosts marketing-led customer engagement and commercial growth.
  • Precision AQ’s 2025 Phluence investment advances agentic patient solutions, reducing post-Rx service costs.

What critics are saying

  • Precision AQ reported $314.5 million revenue in 2024, down 7%, signaling slower growth.
  • Phluence integration in November 2025 risks distracting teams while AI patient-service economics remain unproven.
  • If pharma shifts to in-house AI access tools, Precision AQ’s HUB model weakens.

What makes Precision AQ unique

  • Precision AQ works with all top 30 pharma companies and 350+ active engagements in 2026.
  • Its 2024 rebrand unified pricing, HEOR, medical affairs, and omnichannel capabilities under one platform.
  • Precision AQ has launched over 450 drugs, creating embedded launch expertise across therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Life Insurance
  • Disability Insurance
  • Paid Vacation
  • Paid Sick Leave
  • Parental Leave
  • Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...